Data Driven Bioscience
Executive Summary
Data Driven Bioscience (DDB) is a specialized molecular diagnostics and computational biology company operating at the intersection of genomics, artificial intelligence, and oncology. Based in Durham, North Carolina—within the vibrant Research Triangle Park biotechnology hub—the company develops and deploys advanced machine learning models and genomic analysis pipelines to solve complex challenges in cancer diagnosis, prognosis, and treatment selection. By translating high-throughput sequencing data into clinically actionable insights, Data Driven Bioscience enables oncologists, clinical researchers, and pharmaceutical companies to realize the promise of precision medicine.
Continue…
Company Overview
The primary mission of Data Driven Bioscience is to alleviate the data bottleneck in precision oncology. While Next-Generation Sequencing (NGS) has become cheaper and more accessible, the capacity to interpret vast genomic, transcriptomic, and epigenomic datasets remains a major hurdle for clinical adoption.
Data Driven Bioscience addresses this gap by creating intelligent software solutions and molecular diagnostic tests. The company leverages proprietary machine learning algorithms trained on massive, curated bio-oncology databases to identify disease signatures, predict patient outcomes, and match patients with optimal targeted therapies or clinical trials.
Core Technology and Methodology
Data Driven Bioscience's proprietary technology platform relies on three core competencies:
- Multi-Omics Integration: Rather than analyzing DNA mutations in isolation, the company's platform integrates multiple layers of biological data, including somatic mutations, copy number variations (CNVs), RNA expression patterns, and DNA methylation profiles. This holistic view provides a highly accurate representation of the tumor microenvironment and tumor biology.
- Advanced Machine Learning: DDB uses pattern recognition algorithms to identify complex, non-linear biomarkers that escape traditional statistical analyses. These models are validated against clinically annotated public and private cohorts to ensure diagnostic accuracy and therapeutic relevance.
- Automated Clinical Reporting: The platform converts raw genomic data (FASTQ/BAM files) into clear, structured clinical reports. These reports highlight actionable variants, specify matching FDA-approved drugs, flag potential resistance mechanisms, and list active clinical trials.
Products and Solutions
Glisign
Glisign is the company's flagship molecular diagnostic and prognostic classifier designed specifically for gliomas (brain tumors). Gliomas are highly heterogeneous and notoriously difficult to classify using traditional histology alone.
* Mechanism: Glisign utilizes machine learning models to analyze specific genomic and transcriptomic signatures from a patient's tumor sample.
* Clinical Utility: It classifies gliomas into distinct molecular subtypes, predicts overall survival rates, and assesses the likelihood of response to specific chemotherapeutic regimens and radiotherapies. This allows neuro-oncologists to avoid over-treating low-risk patients or under-treating high-risk patients.
Genomic Interpretation Engines
DDB offers automated computational pipelines for clinical laboratories running in-house NGS panels.
* Variant Annotation: Real-time annotation of single nucleotide variants (SNVs), indels, and structural variants using up-to-date oncology knowledge bases.
* Immunotherapy Biomarker Assessment: Automated calculation of Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) status from tumor-only or tumor-normal sequencing data, which are critical metrics for prescribing immune checkpoint inhibitors.
Services Offered
Bioinformatics and Computational Biology Services
Data Driven Bioscience operates as a contract research partner for academic medical centers, health systems, and biotechnology companies. These services include:
* Custom Pipeline Development: Building bespoke, cloud-based bioinformatics workflows tailored to specific research instruments or diagnostic panels.
* Single-Cell RNA Sequencing (scRNA-seq) Analysis: Providing cellular-level resolution of tumor heterogeneity, immunology, and therapy resistance profiles.
* Bulk Transcriptomics and Epigenomics: Analyzing large-scale RNA-seq and DNA methylation datasets to identify differentially expressed pathways and epigenetic silencing events.
Companion Diagnostic (CDx) Development
DDB partners with pharmaceutical companies to develop companion diagnostics that run alongside novel therapeutics.
* Biomarker Identification: Utilizing unsupervised machine learning to find novel patient responder profiles during Phase I and Phase II clinical trials.
* Trial Stratification: Helping clinical trial sponsors screen and enroll patient populations matching highly specific molecular criteria, increasing the probability of trial success.
Target Markets and Applications
Data Driven Bioscience serves three primary segments within the healthcare and life sciences ecosystem:
- Clinical Oncology Practices: Providing diagnostic reports that assist community and academic oncologists in making personalized treatment decisions for complex cancer cases.
- Biopharmaceutical Companies: Assisting drug developers in identifying novel targets, understanding drug resistance mechanisms, and optimizing clinical trial designs through biomarker discovery.
- Academic and Clinical Research Institutions: Supporting large-scale genomic discovery projects with advanced analytical horsepower and statistical modeling.
